Apton Biosystems Raises $24M in Series A Financing
- Apton Biosystems, Inc., a Pleasanton, CA-based developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications
- The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures
- Concurrent with the financing, Jay Kern of Kern Capital has joined Apton’s board of directors
- The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems
- The company is a developer of Super-Res™ sequencing and single-molecule detection systems for large-scale clinical applications
- Its Super-Res™ technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs
